Pulse Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-9.9%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$1.9Mnext fiscal year
FY EPS (est.)
-$1.11next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 16 Nov 2026 |
Monitoring Framework
Key Performance Indicators
NANOPULSE-AF Study Enrollment Quarterly7.0Target: 145 patients
Product Revenue Quarterly401KTarget: Commercial scaling
Cash and Cash Equivalents Quarterly68.3MTarget: Sufficient runway for clinical milestones
Watch Items
- NANOPULSE-AF clinical trial progress and follow-up dataTrigger: Completion of enrollment of 145 patients across up to 30 sitesAction: Evaluate safety and efficacy endpoints to support FDA submission
- CE Mark submission for nPulse cardiac catheterTrigger: Submission targeted for second half of 2026Action: Monitor regulatory feedback and prepare for potential 2027 European approval
- Vybrance platform commercialization and PRECISE trial expansionTrigger: Expansion of PRECISE benign thyroid nodule study to 100 patientsAction: Assess clinical data and secure labeling/reimbursement clarity over the next 4 to 8 quarters
Research as of 19 Jun 2026